Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics
Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
Determine which no fee travel card is better suited for you. Make the right choice for your travel goals and preferences.
22,600 articlesImmunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a stra...
SoFi’s five-year arc has been a brutal test of conviction: a steep drawdown followed by a rebound as the fintech seek...
U.S. equities drift as tariff uncertainty lingers, with the S&P 500 and SPY easing while investors await policy clari...
Global markets brace for potential price pressures as El Niño-linked commodity risks rise. This report outlines actio...
When a fintech stalwart like Fiserv experiences a pullback, it can ripple through the broader market. This guide expl...
Ben Chester navigated a path from crushing debt renting to a thriving landlord with eight properties, three short-ter...
Inflation trends keep shifting, and the fed's latest inflation forecast is a key signal for investors. This guide bre...
As SpaceX readiness enters the Russell 1000 framework, investors ask if the Vanguard VONG ETF belongs in a growth por...
Two popular healthcare ETFs sit at the crossroads of broad exposure and biotech precision. This guide helps you decid...
As AI data centers demand more power, nuclear options like NuScale Power and Constellation Energy rise in relevance. ...
Choosing between climate-aligned global ETFs and broad international funds can shape your portfolio for years. This g...
Choosing the right ETF can feel like choosing the right map for a long journey. This guide breaks down which better E...